Browsing Tag

Repertoire Immune Medicines

1 post

Repertoire Immune Medicines is a clinical-stage biotechnology firm developing medicines that unlock and utilize the massive potential of the human immune system to prevent or treat cancer, as well as autoimmune and viral diseases.

Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors

BioTech Health X

May 4, 2021

Biotech NewsRepertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors

3 minute read

The collaboration between Repertoire and Yale seeks to identify novel antigenic reactivity of T cells in patients with…

Repertoire Immune Medicines

Biotech NewsRepertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors

Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results

CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections

Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Hello, I’m
BioTech Health X